UNUSUAL CASE OF ANTI-SYNTHETASE SYNDROME CORRELATED WITH EXPOSURE TO COVID-19 INFECTION OR VACCINE
Chest
; 162(4):A2165, 2022.
Article
in English
| EMBASE | ID: covidwho-2060905
ABSTRACT
SESSION TITLE Systemic Disease with Diffuse Lung Symptoms Case Posters SESSION TYPE Case Report Posters PRESENTED ON 10/17/2022 1215 pm - 0115 pm INTRODUCTION:
Since its first detection at Wuhan, China, SARS-CoV-2 (novel coronavirus 2019) has engulfed the world with more than 100 million cases and manifestations of COVID19 have been evolving over time. Various post COVID19 syndromes are being recognized. Reactive arthritis, connective tissue disorders such as myositis and pulmonary complications have been correlated with exposure to COVID infection. We describe the case of antisynthetase syndrome in a patient correlated with exposure to COVID infection or vaccine. CASE PRESENTATION A 68 year old female with history of hypertension and exposure to COVID infection in the family member, presented with 2-3 months worsening generalized body ache/pain started 2 weeks after receiving second dose of mRNA vaccine. Patient also reported dyspnea and leg swelling for 1 month. Upon presentation, she was placed on 4 liter oxygen via nasal cannula. Chest x-ray concerning for infiltrates, possibly COVID. CT chest no pulmonary embolism but evidence of pneumonia superimposed on chronic appearing bronchiectasis. Flu and Covid testing were negative. Patient was started on IV antibiotics for community acquired pneumonia. Labs showed elevated ESR, CRP and CK level. No fever, weakness, mechanics hands, rash or Raynaud's phenomenon. Infectious work up remained negative. No lymphadenopathy on CT chest to suggest sarcoid. ACE level normal. ANA and anti aminoacyl-tRNA synthetase antibody positive but other ENA were negative. HMG-COA ab negative. MPO/PR3 neg. Echocardiogram was unremarkable. Work up was suggestive of Anti synthetase syndrome with interstitial lung disease(ILD), a form of dermatomyositis. Patient was started on intravenous steroid with good improvement in symptoms and later transitioned to oral prednisone. Patient was discharged on minimal home oxygen with plan to start immunosuppressive medications.DISCUSSION:
We are unsure if our patient had COVID19 infection since COVID testings were negative (antigen, antibody and nucleic acid detection ). The likelihood of autoimmune and rheumatic diseases in COVID19 survivors is a big issue. COVID19 infection may unmask previously undiagnosed rheumatic conditions and precipitate de novo disease, both of which may persist after resolution of the initial infection. Corticosteroids remain the cornerstone of early treatment with initial doses at 1mg/kg of the ideal body weight. In an effort to reduce steroid related side effects, other immunosuppressive agents should be considered at the outset of therapy, particularly when treating anti-synthetase syndrome with manifestations of ILD.CONCLUSIONS:
Patients with anti-synthetase syndrome with ILD could have correlation with exposure to COVID infection or vaccination, and are steroid responsive. It is likely that clinical improvement may result from prompt suppression of inflammatory systemic response by corticosteroid. Reference #1 1. Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol. 2021;40(7)2611-2619. doi10.1007/s10067-021-05691-x Reference #2 2. Witt LJ, Curran JJ, Strek ME. The Diagnosis and Treatment of Antisynthetase Syndrome. Clin Pulm Med. 2016;23(5)218-226. doi10.1097/CPM.0000000000000171 DISCLOSURES No relevant relationships by ELINA MOMIN No relevant relationships by Mohammedumer Nagori
3 hydroxy 3 methylglutaryl coenzyme A; amino acid transfer RNA ligase; antibiotic agent; corticosteroid; dipeptidyl carboxypeptidase; endogenous compound; immunosuppressive agent; oxygen; prednisone; RNA vaccine; unclassified drug; adverse drug reaction; aged; antigen antibody complex; antisynthetase syndrome; autoimmune disease; body weight; bronchiectasis; case report; China; clinical article; community acquired pneumonia; conference abstract; connective tissue disease; coronavirus disease 2019; dermatomyositis; diagnosis; drug therapy; dyspnea; echocardiography; female; fever; gene expression; hand rash; hospital discharge; human; hypertension; ideal body weight; influenza; interstitial lung disease; intravenous drug administration; leg swelling; long COVID; lung complication; lung disease; lung embolism; lymphadenopathy; myositis; nasal cannula; nonhuman; nucleic acid analysis; pain; pneumonia; precipitation; Raynaud phenomenon; reactive arthritis; rheumatic disease; sarcoidosis; Severe acute respiratory syndrome coronavirus 2; side effect; survivor; systemic disease; thorax radiography; vaccination; weakness
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Chest
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS